IPOs, People

Belldegrun and Chang groom their biotech unicorn Allogene for a monster $288M — or so — IPO

Arie Belldegrun and David Chang are thinking big again, of course.

Today the pair running the biotech startup Allogene, a CAR-T company $ALLO looking to make history pioneering off-the-shelf cell therapeutics, outlined plans to sell 16 million shares in the company at $16 to $18 a share. That’s $288 million at the top of the range — though these 2 may not be satisfied with anything less than more.


According to Renaissance Capital, the IPO assigns Allogene a fully diluted market value of $2.1 billion and an enterprise value of $1.4 billion. Belldegrun will own 10.9% of that, according to the S-1, while Chang, the CEO, is in for 3.9%.

Allogene landed with a mighty splash in 2017, arriving complete with a portfolio of drugs it had in-licensed from Pfizer and a rep that Belldegrun & Chang had forged at Kite — acquired for $12 billion — for building top-performing teams which knew how to move fast.

In short order they raised a $300 million round in the spring, quickly followed by a $120 million more and now something on the order of $300 million to add to that. That would be more than $700 million in 6 months time.

It’s likely to set the record for biotech IPOs this year, which is shaping up as one of the biggest — of not the biggest — years in the past decade. Rubius achieved a total of around $277 million — a jaw-dropping amount for a preclinical company.

Goldman Sachs, JP Morgan, Cowen and Jefferies are the joint bookrunners on the deal, which analysts expect to price during the week of October 8, coming up.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 33,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Scientist, Quality Control
Molecular Templates Austin, TX
Receptionist/Administrative Assistant
Molecular Templates Austin, TX
Principal
Flagship Pioneering Cambridge, MA

Visit Endpoints Careers ->